CTIS2022-502401-15-00招募中1 期
NB003-01
ingbo Newbay Technology Development Co. Ltd.0 个研究点目标入组 290 人开始时间: 2023年3月1日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 290
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinomaTreatment of human papilloma virus (HPV) associated infections and cancersMedDRA version: 20.1Level: LLTClassification code: 10063001Term: Human papilloma virus infection Class: 10021881CTIS2024-514413-36-00Bluesky Immunotherapies GmbH12
进行中（未招募）
1 期
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code: 10018937Term: Haemophilia A Class: 10010331CTIS2023-505801-17-00Swedish Orphan Biovitrum AB (publ)24
进行中（未招募）
1 期
Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteersMedDRA version: 21.1Level: LLTClassification code: 10045023Term: Tuberculosis prophylaxis Class: 10042613MedDRA version: 21.1Level: PTClassification code: 10072084Term: Tuberculosis immunisation Class: 100000004865TuberculosisCTIS2023-509515-89-00BioNTech SE128
进行中（未招募）
1 期
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)Metastatic cancer, Epithelial tumoursCTIS2023-503525-19-00Akamis Bio Limited220
招募中
1 期
Dose escalation trial of BNT152+153 in patients with cancerVarious solid tumors that are metastatic or unresectableMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-509508-13-00BioNTech SE4